Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Triple Negative Breast Neoplasms|Triple-Negative Breast Cancer
Interventions: BIOLOGICAL: Personalized synthetic long peptide vaccine (Poly ICLC)|DRUG: Poly ICLC
Sponsor: Washington University School of Medicine
Collaborators: Susan G. Komen Breast Cancer Foundation